Striant Testosterone Buccal System: No Adverse Effects on Hearing in American Males

Introduction

Testosterone replacement therapy (TRT) has become a widely utilized treatment for hypogonadism in American males, with various delivery methods available, including the Striant testosterone buccal system. This innovative approach to TRT involves a bioadhesive tablet that is placed in the buccal cavity, allowing for the gradual release of testosterone into the bloodstream. While the efficacy of Striant in improving symptoms of hypogonadism is well-documented, its potential impact on auditory health remains an area of interest. This article presents the findings of a 9-month audiological study investigating the effects of the Striant testosterone buccal system on hearing in American males.

Study Design and Methodology

The study involved a cohort of 120 American males aged 40-65 years with confirmed hypogonadism, who were prescribed the Striant testosterone buccal system as part of their TRT. Participants underwent comprehensive audiological assessments at baseline, 3 months, 6 months, and 9 months following the initiation of treatment. These assessments included pure-tone audiometry, speech audiometry, and otoacoustic emissions testing to evaluate the participants' hearing thresholds, speech discrimination abilities, and cochlear function, respectively.

Results: Hearing Thresholds and Speech Discrimination

Over the course of the 9-month study, no significant changes were observed in the participants' pure-tone hearing thresholds across all frequencies tested (250 Hz to 8000 Hz). The mean hearing thresholds remained stable, with no statistically significant differences between the baseline and subsequent assessments. Similarly, speech discrimination scores, as measured by the word recognition test, showed no significant changes throughout the study period. These findings suggest that the use of the Striant testosterone buccal system does not adversely affect hearing sensitivity or speech understanding in American males undergoing TRT.

Results: Otoacoustic Emissions

Otoacoustic emissions (OAEs) are low-intensity sounds generated by the cochlea in response to auditory stimuli and serve as an indicator of cochlear health. In this study, distortion product otoacoustic emissions (DPOAEs) were measured to assess the potential impact of the Striant testosterone buccal system on cochlear function. The results demonstrated that DPOAE amplitudes remained stable across all frequencies tested (1000 Hz to 8000 Hz) throughout the 9-month study period. No significant differences were observed between the baseline and subsequent assessments, indicating that the use of Striant does not negatively affect cochlear function in American males.

Discussion and Clinical Implications

The findings of this 9-month audiological study provide reassuring evidence that the Striant testosterone buccal system does not adversely affect hearing in American males undergoing TRT. The stability of hearing thresholds, speech discrimination scores, and otoacoustic emissions suggests that the use of Striant is safe from an audiological perspective. These results are particularly important given the increasing prevalence of hypogonadism and the growing use of TRT in the American male population.

Clinicians prescribing the Striant testosterone buccal system can confidently inform their patients that this form of TRT is unlikely to impact their hearing health. However, it is essential to continue monitoring patients' auditory function as part of routine follow-up care, as individual responses to TRT may vary. Further research is warranted to investigate the long-term effects of Striant on hearing and to explore potential differences in audiological outcomes among diverse patient populations.

Conclusion

In conclusion, this 9-month longitudinal study demonstrates that the Striant testosterone buccal system does not negatively impact hearing in American males undergoing TRT for hypogonadism. The stability of hearing thresholds, speech discrimination, and otoacoustic emissions throughout the study period provides reassurance regarding the audiological safety of this treatment modality. As the use of TRT continues to rise, these findings contribute to the growing body of evidence supporting the safe and effective use of the Striant testosterone buccal system in American men.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.